Lantheus Holdings, Inc.(LNTH)— Stock Profile, AI Score & Financials
Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated .
Lantheus Holdings, Inc. (LNTH) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores LNTH at 61.1/100 on a 32-signal composite quality model, placing it at rank #814 of 2,960 stocks — the top half of the AI-ranked universe. LNTH scores in the top quartile across balance sheet strength (89.2), free cash flow (80.3), profitability (76.1). Areas of concern include institutional flow (35.4), which score below median versus the broader universe. Shareholder dilution risk is elevated at 23.5/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Lantheus Holdings, Inc. reports quarterly revenue of $388.2M, net income of $75.0M, an operating margin of 25.8%. Top institutional holders of LNTH by reported 13-F value include BlackRock, FARALLON CAPITAL MANAGEMENT, Jupiter Topco, based on the most recent SEC filings. LNTH trades on the Nasdaq exchange and files with the SEC under CIK 1521036. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate LNTH daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Lantheus Holdings, Inc. directly from SEC EDGAR.
AI Quality Score
61.1/100
AI Rank
#814
Revenue
$388.2M
Net Income
$75.0M
Operating Margin
25.8%
LNTH key financials by period
Lantheus Holdings, Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
Period
Form
Revenue
Net income
Operating margin
FY 2025
10-K
$1.5B
$233.6M
20.2%
FY 2024
10-K
$1.5B
$312.4M
29.8%
FY 2023
10-K
$1.3B
$326.7M
28.1%
FY 2022
10-K
$935.1M
$28.1M
3.9%
FY 2021
10-K
$425.2M
$-71.3M
-14.3%
FY 2020
10-K
$339.4M
$-13.5M
-1.2%
Institutions holding LNTH
Institutional investors reporting a position in Lantheus Holdings, Inc. on SEC Form 13F.
AI-extracted from the 10-Q filed 2026-05-07 — Q1 2026 (quarter ended March 31, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.
Q1 revenue $377.3M (+1.2% YoY) driven by Neuraceq contribution post-Lantheus Biosciences acquisition and DEFINITY growth, offset by PYLARIFY pricing pressure; net income $118.4M (+62% YoY) boosted by $59.3M SPECT business sale gain.
Biggest Revenue Drivers
PYLARIFY (Oncology)$240.9M-6.5% YoY
Decreased due to lower net sales price in 2026, partially offset by increased sales volume.
DEFINITY (Cardiology)$84.6M+6.8% YoY
Increased from higher sales volume.
Biggest Revenue Drivers
Total revenue: $377.3M+1.2% YoY
PYLARIFY (Oncology)$240.9M-6.5% YoY
Decreased due to lower net sales price in 2026, partially offset by increased sales volume.
DEFINITY (Cardiology)$84.6M+6.8% YoY
Increased from higher sales volume.
Neuraceq (Neurology)$35.4M+100.0% (from $0M)
New contribution following Lantheus Biosciences acquisition in July 2025; no comparable prior-year revenue.
Strategic Partnerships and Other$16.3M+52.1% YoY
Increased from CDMO revenue generated post-Evergreen Therapeutics acquisition and MK-6240 investigational use revenue.
Largest Expense Items
Cost of goods sold$146.4M+8.4% YoY
Increased due to lower PYLARIFY net sales price, higher intangible asset amortization from Lantheus Biosciences acquisition, and SPECT business sale, partially offset by Neuraceq gross profit.
Sales and marketing$52.7M+24.0% YoY
Increased due to employee-related costs for Neuraceq sales and marketing expenditures for PYLARIFY TruVu launch preparation.
Research and development$39.4M+8.4% YoY
Increased from impacts of Lantheus Biosciences and Evergreen acquisitions and LNTH-2403 project costs, partially offset by lower regulatory payments compared to prior year.
General and administrative$57.5M+1.3% YoY
Increased modestly due to acquisition integration costs, offset by reduced litigation costs and legal settlement received in Q1 2026.
Watch Items from the Filing
PYLARIFY revenue declined 6.5% YoY to $240.9M due to net sales price reductions effective January 1, 2025, when CMS transitioned from transitional pass-through payment to mean unit cost methodology; competitive PSMA agents retain higher TPT Status payments.
LNTH-2501 NDA review extended to June 29, 2026 from March 29, 2026 for manufacturing-related information review; FDA tentative approval of PNT2003 ANDA received March 2, 2026 but subject to 30-month Hatch-Waxman stay and ongoing patent litigation.
Company received $59.3M gain on SPECT business sale to Illuminated but future consideration includes unsecured $20M seller note, $20M deferred cash (or $25M if unpaid by Jan 1, 2030), and contingent payments up to $30M based on unachieved revenue milestones.
Significant contingent liabilities from acquisitions: Evergreen up to $727.5M in milestone payments; Lantheus Biosciences up to $400M earn-out/milestone payments on Neuraceq sales plus $30M to Piramal based on earnings metrics.
Advanced Accelerator Applications (Novartis) patent infringement litigation over PNT2003 ANDA pending court decision as of filing date; putative securities class action consolidated in Southern District of New York with amended complaint filed March 13, 2026 alleging false statements regarding business performance.
AI-extracted and verified against SEC EDGAR filing text. Not investment advice.
